REAC

ReacX Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on long-acting implantable therapies for chronic diseases, with an initial emphasis on substance use disorders. The company's core asset is ProNeura, a proprietary subdermal drug delivery platform designed to provide continuous, controlled medication release for six months or longer. ReacX is advancing a nalmefene implant in Phase 1 for relapse prevention in opioid use disorder and is also working to relaunch Probuphine, an FDA-approved buprenorphine implant previously marketed for opioid addiction maintenance treatment. The company acquired Probuphine and the underlying ProNeura technology and is positioning the platform for additional chronic disease applications, including chronic pruritus. ReacX appears to operate from South San Francisco, California and has been supported by non-dilutive funding from the National Institute on Drug Abuse.